REG - Ergomed plc - Exercise of Options & Issue of Equity

ErgomedAnnouncement

01/02/2019 11:35

RNS Number : 8557O
Ergomed plc
01 February 2019
 


PRESS RELEASE
   FOR IMMEDIATE RELEASE
 
 
 
Exercise of Options and Issue of Equity
 
Guildford, UK - 1 February 2019: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, has issued and allotted 1,000,000 new ordinary shares of 1p each in the Company ("New Ordinary Shares") following the exercise by a former employee of options awarded under the Company's Unapproved Executive Share Option Scheme 2007.
 
Accordingly, an application has been made for the 1,000,000 New Ordinary Shares to be admitted to trading on AIM ('Admission'). It is expected that Admission will occur at 8:00 a.m. on 5 February 2019. The New Ordinary Shares will rank pari passu with the existing ordinary shares in the Company.
 
Following Admission, the Company's enlarged issued share capital will comprise 46,016,438 ordinary shares with one voting right per share. No shares are held in Treasury. The total number of voting rights in the Company is therefore 46,016,438.
 
This figure of 46,016,438 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
- Ends -
 
Enquiries:
 



Ergomed plc


   Tel: +44 (0) 1483 503205




Dr Miroslav Reljanovic (Executive Chairman)








Stuart Jackson (Chief Financial Officer)


















Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Michael Meade / Freddie Barnfield (Nominated Adviser)








James Black (Broker)


















Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Mary-Jane Elliott


ergomed@consilium-comms.com




Matthew Neal / Olivia Manser


















MC Services - for Continental European enquiries


Tel: +49 211 5292 5222




Anne Hennecke







 
 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOEEAFAFEDENEFF